联合胰液甲基化DNA标志物与血浆CA 19-9的多模态胰腺癌检测:一项前瞻性多中心研究
本前瞻性多中心研究对88例活检证实、未接受治疗的胰腺导管腺癌(PDAC)患者和134例对照(53例胰腺正常、23例慢性胰腺炎、58例导管内乳头状黏液性肿瘤)配对检测胰液(PJ)甲基化DNA标志物(MDM)与血浆CA 19-9。3-MDM PJ联合血浆CA 19-9模型的AUROC为0.95,高于3-MDM PJ面板的0.87和单用血浆CA 19-9的0.91。在特异性88%时,该模型对全部PDAC的敏感性为89%,对I/II期PDAC为83%。
要点
- 3-MDM PJ联合血浆CA 19-9模型AUROC 0.95,高于3-MDM PJ面板0.87和单用CA 19-9的0.91。
- 在特异性88%时,联合模型对全部PDAC敏感性89%,对I/II期PDAC敏感性83%。
- 甲基化FER1L4单项AUROC最高,为0.83。
核心结论
- 联合PJ-MDM与血浆CA 19-9的面板能以高准确度区分PDAC与健康对照及疾病对照组。
- 该结果为联合胰液与血液生物标志物以提高诊断敏感性和实现PDAC早期检测提供了支持。
研究设计与样本
- 前瞻性多中心研究,纳入88例活检证实、未接受治疗的PDAC病例和134例对照(53例胰腺正常、23例慢性胰腺炎、58例导管内乳头状黏液性肿瘤)。
- 配对检测胰液和血浆;胰液经亚硫酸氢盐转化后,用长探针定量扩增信号法检测14种MDM(NDRG4、BMP3、TBX15、C13orf18、PRKCB、CLEC11A、CD1D、ELMO1、IGF2BP1、RYR2、ADCY1、FER1L4、EMX1、LRRC4)及参考基因甲基化B3GALT6。
- 用逻辑回归拟合既往确定的3-MDM PJ面板(FER1L4、C13orf18、BMP3);以AUROC及95%CI汇总判别准确度。
主要发现
- 甲基化FER1L4单项AUROC最高,为0.83(95%CI,0.78-0.89)。
- 3-MDM PJ联合血浆CA 19-9模型AUROC为0.95(95%CI,0.92-0.98),高于3-MDM PJ面板的0.87(95%CI,0.82-0.92)(P=.0002)。
- 3-MDM PJ联合血浆CA 19-9模型AUROC为0.95(95%CI,0.92-0.98),高于单用血浆CA 19-9的0.91(95%CI,0.87-0.96)(P=.0135)。
- 在特异性88%(95%CI,81%-93%)时,该模型对全部PDAC的敏感性为89%(95%CI,80%-94%),对I/II期PDAC的敏感性为83%(95%CI,64%-94%)。
关键数值与推荐
- 3-MDM PJ联合血浆CA 19-9模型:AUROC 0.95(95%CI,0.92-0.98)。
- 3-MDM PJ面板:AUROC 0.87(95%CI,0.82-0.92)。
- 单用血浆CA 19-9:AUROC 0.91(95%CI,0.87-0.96)。
- 甲基化FER1L4单项:AUROC 0.83(95%CI,0.78-0.89)。
- 特异性88%(95%CI,81%-93%)时,联合模型对全部PDAC敏感性89%(95%CI,80%-94%),对I/II期PDAC敏感性83%(95%CI,64%-94%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In previous studies, methylated DNA markers (MDMs) have been identified in pancreatic juice (PJ) for detecting pancreatic ductal adenocarcinoma (PDAC). In this prospective multicenter study, the sensitivity and specificity characteristics of this panel of PJ-MDMs was evaluated standalone and in combination with plasma carbohydrate antigen 19-9 (CA 19-9). METHODS: Paired PJ and plasma were assayed from 88 biopsy-proven treatment-naïve PDAC cases and 134 controls (53 with normal pancreas, 23 with chronic pancreatitis [CP], 58 with intraductal papillary mucinous neoplasm). Bisulfite-converted DNA from buffered PJ was analyzed using long-probe quantitative amplified signal assay targeting 14 MDMs (NDRG4, BMP3, TBX15, C13orf18, PRKCB, CLEC11A, CD1D, ELMO1, IGF2BP1, RYR2, ADCY1, FER1L4, EMX1, and LRRC4) and a reference gene (methylated B3GALT6). Logistic regression was used to fit the previously identified 3-MDM PJ panel (FER1L4, C13orf18, and BMP3). Discrimination accuracy was summarized using area under the receiver-operating characteristic curve (AUROC) with corresponding 95% confidence interval (CI). RESULTS: Methylated FER1L4 had the highest individual AUROC of 0.83 (95% CI, 0.78-0.89). The AUROC for the 3-MDM PJ + plasma CA 19-9 model (0.95; 95% CI, 0.92-0.98) was higher than both the 3-MDM PJ panel (0.87; 95% CI, 0.82-0.92)) and plasma CA 19-9 alone (0.91; 95% CI, 0.87-0.96) (P = .0002 and .0135, respectively). At a specificity of 88% (95% CI, 81%-93%), the sensitivity of this model was 89% (95% CI, 80%-94%) for all PDAC stages and 83% (95% CI, 64%-94%) for stage I/II PDAC. CONCLUSIONS: A panel combining PJ-MDMs and plasma CA 19-9 discriminates PDAC from both healthy and disease control groups with high accuracy. This provides support for combining PJ and blood-based biomarkers for enhancing diagnostic sensitivity and successful early PDAC detection.
引用
- Engels MML, Berger CK, Mahoney DW, et al. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Clin Gastroenterol Hepatol. 2024. PMID: 39477082. doi:10.1016/j.cgh.2024.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。